Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer by Watanabe, R et al.
Feasibility of combination chemotherapy with cisplatin and
etoposide for haemodialysis patients with lung cancer
R Watanabe
1, Y Takiguchi*
,1, T Moriya
1, S Oda
2, K Kurosu
1, N Tanabe
1, K Tatsumi
1, K Nagao
3 and T Kuriyama
1
1Department of Respirology (B2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan;
2Department of
Emergency and Critical Care Medicine (J3), Graduate School of Medicine, Chiba University, Chiba, Japan;
3Health Sciences Center, Chiba University,
Chiba, Japan
Cancer chemotherapy for haemodialysis patients has never been established. To elucidate the feasibility of cisplatin-based
combination chemotherapy for haemodialysis patients with lung cancer, a dose escalation study was conducted. Five haemodialysis
patients with lung cancer were treated with cisplatin and etoposide. A starting dose of 40mgm
 2 of cisplatin on day 1 and
50mgm
 2 of etoposide on days 1, 3 and 5 were administered as the first course for the first patient. Membrane haemodialysis was
regularly performed three times a week and soon after the completion of therapy. By monitoring toxicity and pharmacokinetics data,
the dose was escalated course by course and patient by patient. Dose escalation was completed for the first two patients resulting in
full-dose chemotherapy consisting of 80mgm
 2 of cisplatin on day 1 and 100mgm
 2 of etoposide on days 1, 3 and 5. Multiple
courses of the full-dose chemotherapy were administered to the other three patients. Toxicity was manageable and tolerable for all.
Pharmacokinetics data were comparable to those from patients with normal renal function, except for potential long-lasting higher
levels of free platinum in the renal insufficiency group. In conclusion, this standard-dose combination chemotherapy was feasible even
for haemodialysis patients.
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Recent advances in haemodialysis for patients with renal
insufficiency have resulted in longer survival than ever. Conse-
quently, they have equal or increased risk of suffering from various
neoplastic diseases, including primary lung cancer (Maisonneuve
et al, 1999). A standard treatment for small-cell lung cancer and
advanced nonsmall-cell lung cancer is the cisplatin-based combi-
nation chemotherapy (Evans et al, 1985; Johnson, 2000). However,
as its principal elimination route is renal (Belt et al, 1979; Gormley
et al, 1979), it has never been routinely administered to patients
with renal insufficiency undergoing haemodialysis. Most previous
studies on chemotherapy for such patients have reported the
feasibility of cisplatin administration at lower than standard doses,
in limited patient numbers (Ayabe et al, 1989; Umeki et al, 1990;
Ono et al, 1992). Chemotherapy consisting of such low doses of
cisplatin, however, has never been shown to be sufficiently
effective for lung cancer, either the small-cell or nonsmall-cell
variety.
To determine adequate dose levels of the combination
chemotherapy of cisplatin and etoposide for haemodialysis
patients, a dose escalation study was conducted in a limited
number of patients under the guidance of pharmacokinetics
monitoring.
PATIENTS AND METHODS
Patients
Five patients with lung cancer and renal insufficiency undergoing
haemodialysis, three with stage IV or recurrent adenocarcinoma
and two with small-cell lung carcinoma, were enrolled in this
study. Characteristics of the five patients are listed in Table 1.
Three other patients with small-cell lung cancer and normal renal
function were enrolled for pharmacokinetics comparison. Written
informed consent was obtained from all the patients. The study
fully complied with institutional regulations. Two of the five
patients had previous cancer therapies. Case 4 (Table 1) had
resection and radiotherapy of laryngeal carcinoma 8 years earlier,
resection of primary lung cancer 5 years earlier, and radiotherapy
for pulmonary recurrence 1 year before the second pulmonary
recurrence of lung cancer and enrolment in the study. Case 5
(Table 1) had trans-urethral resection of bladder cancer 2 years
before the development of primary lung cancer and enrolment in
the study. The other three patients had had no prior chemotherapy
or radiotherapy.
Haemodialysis
All five patients with renal insufficiency had been maintained with
regular three-times-a-week haemodialysis utilising membrane
filters before entering the study. From the start of the study,
membrane haemodialysis was continued with the exclusive use of
high-performance membranes (BS series, TORAY Medical Co., Received 27 September 2002; accepted 9 October 2002
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lTokyo) three times a week, with a single haemodialysis lasting
approximately 4h. On the days of chemotherapy, haemodialysis
was started within 10min after completion of the administration of
the agents.
Chemotherapy and dose escalation
The chemotherapeutic regimen for the eight patients, the five
haemodialysis patients and the three patients with normal renal
function, consisted of cisplatin on day 1 and etoposide on days 1, 3
and 5, every 4 weeks. The schedule of the administration of the two
agents on day 1 consisted of intravenous injection of etoposide in
500ml of normal saline over 60min, and of cisplatin over 30min
starting 30min after the start of etoposide infusion, resulting in the
simultaneous completion of the two agents. Hydration with 2000ml
of electrolyte solution, on the day before day 1 and with 3000ml of
electrolyte solution on day 1, was performed for the patients with
normal renal function. No hydration was done for the five
haemodialysis patients. All patients received granisetron hydro-
chloride, 6mg i.v. in two fractions, for nausea and vomiting
prophylaxis on day 1. For the three patients with normal renal
function, standard-dose chemotherapy was administered, consist-
ing of cisplatin and etoposide at 80 and 100mgm
 2, respectively.
For the haemodialysis patients, half-dose chemotherapy
(40mgm
 2 of cisplatin on day 1 and 50mgm
 2 of etoposide on
days 1, 3 and 5) was administered for the first course of the first
patient of this group (Case 1, Table 1), based on previously
published reports that these doses were safe even for such patients
(Ono et al, 1992; Yanagawa et al, 1996). Thereafter, the dose
escalation protocol consisted of: (1) pharmacokinetics analysis of
every course immediately after its completion, (2) course-by-course
dose escalation to determine maximum tolerable dose (MTD), but
not to exceed the standard doses for the patients with normal renal
function, (3) initial dose escalation of cisplatin alone with reference
to pharmacokinetics comparison between the previous courses and
average data from the three patients with normal renal function, (4)
dose escalation of etoposide, again with reference to the
pharmacokinetics comparison between the two, (5) one more
repetition of the same dose when dose limiting toxicity (DLT) is
observed, and (6) determination of MTD when DLT is observed in
two successive courses. DLT is defined as any of grade 4
haematological toxicity except anaemia and grade 3 or higher
nonhaematological toxicity except nausea/vomiting and alopecia.
Toxicity caused by the treatment was evaluated according to the
National Cancer Institute Common Toxicity Criteria version 2.0.
Pharmacokinetics study
Venous blood samples were collected into heparinised tubes
immediately upon the completion of drug administration, then at
0.5, 1, 2, 3, 4, 5, 8, 16 and 24h on days 1, 3 and 5, followed by
additional once-a-day sampling on days 7, 14 and 28. After
separating plasma from each sample, concentrations of total
platinum (t-Pt) and etoposide were measured in a portion of the
plasma. The rest was ultrafiltered by centrifuging at 3000rpm for
20min with a filter (Amicon Centrifree MPS-3, Millipore Corp.,
Bedford, MA, USA) and was used for measurement of nonprotein-
bound platinum or free platinum (f-Pt). Separated plasma was
stored at  801C until measurement. Concentrations of t-Pt and
f-Pt were determined by flameless atomic absorption spectro-
photometry (LeRoy et al, 1977), and those of etoposide were
determined by high-performance liquid chromatography (Strife
et al, 1981). Pharmacokinetics data were analysed according to the
previously reported method (Yamaoka et al, 1978). Briefly, all
measurements before the next administration of the same agent
were used for calculations of pharmacokinetics parameters, unless
each measurement was less than 5% of the maximum concentra-
tion (Cmax). When a measurement before the next administration
was less than 5% of Cmax, only measurements before this time
point were used for the calculation of the data.
Dialysability of cisplatin and etoposide
At 10min after the start of each haemodialysis, blood samples were
collected from both import and export sides of the dialyser for the
measurements of f-Pt, t-Pt and etoposide concentrations. Then, the
in situ elimination rate of each agent with the dialysers was
determined by the following formula: elimination rate¼
(concentration in the import side   concentration in the export
side)/concentration in the import side.
Evaluation of tumour response
Objective tumour response was evaluated according to the
‘Response evaluation criteria in solid tumors’ guideline (Therasse
et al, 2000), and the response was classified into the four
categories: complete response, partial response, stable disease
and progressive disease.
Statistical analysis
Comparisons of each pharmacokinetics parameter between patient
groups and dose groups were analysed by Student’s unpaired
t-test. Comparisons of each pharmacokinetics parameter accord-
ing to chemotherapeutic course number were performed with the
Kruskal–Wallis test. Differences were judged as significant when P
values were less than 0.05 (two-sided).
Table 1 Patient characteristics
Case no. Gender Age Histology
a Clinical stage PS
b Cause of renal failure
c Duration of haemodialysis (year)
Case 1 Male 74 Sm T2 N1 M0 1 MPGN 2
Case 2 Female 43 Ad T3 N2 M1 0 IgA 12
Case 3 Male 58 Sm T4 N3 M1 2 DM 6
Case 4 Male 72 Ad recurrence 0 Unknown 1
Case 5 Male 50 Ad T4 N2 M1 0 DM 5
aSm, small-cell lung cancer; Ad, adenocarcinoma of lung.
bPS, performance status (ECOG).
cMPGN, membranoproliferative glomerulonephritis; IgA, IgA nephropathy; DM,
diabetic nephropathy.
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Dose escalation of cisplatin and etoposide in haemodialysis
patients
Dose escalation was completed in the first two cases, and the final
dose level was the same as the standard doses for patients with
normal renal function, that is, 80mgm
 2 of cisplatin and
100mgm
 2 of etoposide. The other three patients were treated
with multiple courses of this dose level to confirm its feasibility.
That is, based on tolerable toxicity and the results of pharmaco-
kinetics (data shown below) with the initial dose (40mgm
 2 of
cisplatin and 50mgm
 2 of etoposide) in the first course of the first
patient, the dose of cisplatin was escalated to 80mgm
 2 with the
etoposide dose being unchanged for the second course of the same
patient (Case 1, Table 1). Then, the dose of etoposide was escalated
to 100mgm
 2, with cisplatin being 40mgm
 2 in the first course of
the second patient (Case 2). Again, based on tolerable toxicity and
pharmacokinetics (data shown below), the standard doses of
80mgm
 2 of cisplatin and 100mgm
 2 of etoposide were
administered in the second course of the same patient (Case 2).
For the other three cases with renal insufficiency, this standard-
dose chemotherapy was performed for four courses in Cases 3 and
5, and for two courses in Case 4, based on their medical
requirements.
Effects of chemotherapy
As for objective tumour response, partial response was obtained in
four of the five cases (Cases 1, 3, 4 and 5). As Case 1 had a limited
disease of small-cell lung cancer, curative-intent thoracic radio-
therapy was performed after the completion of the two courses of
chemotherapy.
Toxicity
Toxicity is summarised in Table 2. Briefly, all five haemodialysis
patients experienced anaemia and neutropenia, and four required
transfusion because of grades 3 and 4 anaemia. Grades 2 and 3
thrombocytopenia were observed in one and two of the patients,
respectively. In Case 2, the start of the second course was
postponed for 1 week because of lingering neutropenia and
anaemia. In Case 3, the start of the third course was put off for 1
week because of lingering neutropenia.
As for nonhaematological toxicity, grade 3 nausea and vomiting
was observed in Cases 4 and 5. On day 5 of the fourth course in
Case 5, the administration of etoposide was skipped because of
prolonged nausea. Other toxicity including liver dysfunction and
pulmonary damage was not observed. Recovery from toxicity was
complete in all the cases.
Pharmacokinetics
Although pharmacokinetics analysis was performed for every
course of each patient and all data were monitored, only a data set
from the first administration of a given dose level of an agent in
each patient was analysed in this presentation to avoid a bias
because of patient variation rather than dose variation. This bias
would be inevitable because some patients were treated with more
courses than others. Therefore, for creating the time–concentra-
tion curves in Figures 1 and 2, data from the first course of Cases 1
and 2 were used for the 40-mgm
 2 cisplatin curves; data from the
second course of Cases 1 and 2, and from the first course of Cases
3–5 were used for the 80-mgm
 2 cisplatin curves; data from the
first course of Case 1 were used for the 50-mgm
 2 etoposide curve;
data from the first course of Cases 2–5 were used for the
100-mgm
 2 etoposide curves. The same data set was used for
calculating the pharmacokinetics parameters according to the dose
of the agent. For etoposide, mean values of each parameter of the
three administrations in each course were used to represent the
course. All data on cisplatin and all the first administrations of
etoposide in each course, however, were used for the calculation of
the pharmacokinetics parameters according to the course number.
Thus, the pharmacokinetics parameters consisting of Cmax, half-
time (t1/2), area under the curve (AUC), total clearance (Cltot) and
volume of distribution (Vdss) of cisplatin and etoposide are
summarised in Tables 3 and 4, respectively. In these tables, the
parameters obtained from the five patients with renal insufficiency
were compared to those from the three patients with normal renal
function. Figures 1 and 2 also compare the concentration–time
curves of cisplatin and etoposide between the patients with renal
insufficiency and with normal renal function.
Cmax and AUC of f-Pt, t-Pt and etoposide were similar between
the two patient groups when the same doses of the agents were
administered, and showed potentially lower levels (approximately
half) than those of half-dose administration to the haemodialysis
patients, although only differences in Cmax and AUC of t-Pt had
Table 2 Toxicity
a
Patient Course no. Anaemia Neutropenia Thrombocytopenia Nausea and vomiting
Case 1 1 2 2 2 2
23 3 3 2
Case 2 1 3 2 0 0
23 3 0 2
Case 3 1 4 3 0 2
24 2 0 2
34 2 0 2
44 2 0 2
Case 4 1 3 3 2 3
24 3 3 3
Case 5 1 3 2 0 3
23 3 0 3
33 3 2 3
43 2 2 3
aGraded by NCI-CTC Version 2.0.
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and Vdss of f-Pt and t-Pt were also similar between the two patient
groups. Vdss of etoposide in the haemodialysis patients was
significantly higher than in the patients with normal renal function
when the same dose (100mgm
 2) was administered (P¼0.034).
Tables 3 and 4 also compare the pharmacokinetics
data according to the course number of chemotherapy in the
haemodialysis patients. Repeated administration showed a ten-
dency to cause increased AUC and decreased Cltot in t-Pt
(P¼0.054 and 0.052, respectively), but not in f-Pt (P¼0.93
and 0.85, respectively) or etoposide (P¼0.97 and 0.97, respec-
tively).
Dialysability of cisplatin and etoposide
Calculated dialysabilities of f-Pt and t-Pt were 86.5722.1 (n¼13)
and 44.0712.0% (n¼14), respectively. In contrast, the calculated
dialysability of etoposide was relatively low at 13.0712.6% (n¼39).
DISCUSSION
As many of the chemotherapeutic agents for cancer involve renal
excretion, cancer chemotherapy for patients with renal insuffi-
ciency undergoing haemodialysis has never been well established.
Several pilot studies concerning the use of certain chemo-
therapeutic agents including cisplatin for haemodialysis patients,
however, have shown the feasibility of such attempts by reducing
the doses of the agents (Ayabe et al, 1989; Umeki et al, 1990; Ono
et al, 1992). Contiguity of therapeutic and toxic dose ranges of the
chemotherapeutic agents, however, casts doubt on the effective-
ness of such significantly dose-reduced chemotherapy. Contrary to
those previous studies, our study demonstrated the feasibility of
full-dose combination chemotherapy with cisplatin and etoposide
in lung cancer patients undergoing haemodialysis.
In this study, half doses of cisplatin and etoposide of the standard
amount were administered in the first course of Case 1, because
these doses were reportedly safe even for such patients (Ono et al,
1992; Yanagawa et al, 1996). Toxicity in the course was well
tolerated. Following this, comparison between the pharmacokinetics
data of this course, the pharmacokinetics data obtained from the
three patients with normal renal function, and previously published
data (Wakui et al, 1986; Kitajima et al, 1987) suggested that these
agents could be doubled in dose. Despite this, however, only
cisplatin was escalated to the standard dose in the second course of
the same patient and, thereafter, only etoposide was escalated to the
standard dose, cisplatin being half of the standard, in the first course
of the second patient. Monitoring of the toxicity and pharmaco-
kinetics data during these chemotherapeutic courses again
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Figure 1 Time–concentration curves of platinum. After 30-min i.v. infusion of cisplatin at doses of 40mgm
 2 (n¼2), 80mgm
 2 (n¼5) for
haemodialysis patients, or 80mgm
 2 (n¼3) for patients with normal renal function, plasma concentrations of f-Pt and t-Pt were sequentially determined.
Each dot and bar represent mean and standard deviation, respectively. Open and closed circles represent f-Pt and t-Pt, respectively, when 40mgm
 2 of
cisplatin was administered to haemodialysis patients. Open and closed triangles represent f-Pt and t-Pt, respectively, when 80mgm
 2 of cisplatin was
administered to haemodialysis patients. Open and closed squares represent f-Pt and t-Pt, respectively, when cisplatin was administered at 80 mgm
 2 to
patients with normal renal function. The lowest detection limit of f-Pt was 25ngml
 1, and measurements below this value were plotted on the dotted line in
this figure. Note that f-Pt levels were still detectable from days 2 to 14 in the haemodialysis patients, whereas those in patients with normal renal function
were all below the detection limit at the same time points.
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Figure 2 Time–concentration curves of etoposide. After 60-min i.v.
infusion of etoposide at doses of 50mgm
 2 (n¼1), 100mgm
 2 (n¼4)
for haemodialysis patients, or 100mgm
 2 (n¼3) for patients with normal
renal function, plasma concentrations of etoposide were sequentially
determined. Each dot and bar represent mean and standard deviation,
respectively. The circles, triangles and squares represent etoposide
concentrations when etoposide was administered at 50 or 100mgm
 2
to haemodialysis patients, or at 100mgm
 2 to patients with normal renal
function, respectively. The lowest detection limit of etoposide was
0.1mgml
 1, and measurements below this value were plotted on the
dotted line in this figure.
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agents. As a result, multiple administrations of full-dose combina-
tion chemotherapy, ranging from two to four courses, were given to
the other three patients. In these patients, toxicity was tolerable and
pharmacokinetics data were comparable to the data obtained from
the three patients with normal renal function, suggesting the safety
of this full-dose combination chemotherapy for haemodialysis
patients. A typical dose escalation test for cancer chemotherapy
usually employs a certain dose level for three to five patients and
when DLT is observed in less than one-third or half of the patients,
the next dose level is administered to the next set of patients.
Contrary to this typical method, the present study performed
course-by-course dose escalation under the guidance of pharmaco-
kinetics analysis. Since the standard dose of this regimen has been
well established for patients with normal renal function, comparison
between pharmacokinetics data obtained from the patients with
normal renal function and course-by-course pharmacokinetics data
from the haemodialysis patients enabled us to accomplish this dose
escalation test in such a small patient number.
Tumour control by this regimen was also satisfactory, with two
partial responses in two patients with small-cell lung cancer and
two partial responses in three patients with nonsmall-cell lung
cancer. Similar dose escalation studies were also reported
previously (Holthuis et al, 1985; Fox et al, 1991), but they involved
a single agent for dose escalation, in contrast to ours, which used a
combination of two agents and their escalated doses. Holthuis et al
(1985) performed combination chemotherapy with cyclophosph-
amide, adriamycin and etoposide for haemodialysis patients with
small-cell lung cancer, and a gradual dose escalation of etoposide
showed that 127mgm
 2 of the agent was feasible. Fox et al (1991)
conducted a dose escalation study with cisplatin, combined with
500mgm
 2 of cyclophosphamide, for haemodialysis patients with
seminoma and showed that 100mgm
 2 of cisplatin was feasible.
Although mechanisms underlying these results have not been
completely understood, the efficient dialysability of f-Pt shown in
the present study may partly explain this phenomenon. As f-Pt is
efficiently cleared by haemodialysis, protein-bound platinum
might be efficiently decomposed to f-Pt in the body. Thus, both
f-Pt and t-Pt might have been cleared as well as in the patients with
normal renal function. Quite contrary to cisplatin, the dialysability
of etoposide was low in this study, while clearance of the agent in
the haemodialysis patients was as efficient as that in patients with
normal renal function. Although this observation is similar to
previously published data (Holthuis et al, 1985; Sauer et al, 1990;
Stewart, 1994), it seems at variance with the excretion routes of this
drug in patients with normal renal function, where it is reportedly
normally eliminated by renal (60%) and hepatic (40%) mechan-
isms (English et al, 1996). Our observation could be explained by
the assumption that the hepatobiliary route completely compen-
sates for the renal route in haemodialysis patients, but our study
did not present any evidence to support this hypothesis. The
increased Vdss of etoposide in the haemodialysis patients suggested
by this study might be a consequence of such altered excretion
route. In any case, the data on dialysability of f-Pt, t-Pt and
Table 3 Pharmacokinetics parameters of platinum
f-Pt t-Pt
Cmax
(lgml
 1) t1/2 (h)
AUC
(lgml
 1h) Cltot (lh
 1) Vdss (l)
Cmax
(lgml
 1) t1/2 (h)
AUC
(lgml
 1h) Cltot (lh
 1) Vdss (l)
Dose
a (mgm
 2)
40
b (n=2) 1.170.21 0.6270.33 1.470.05 44.673.2 43.5719.0 2.270.44 275.4711.8 337782 0.1970.026 73.376.7
80
b (n=5) 1.970.55 0.8270.18 2.770.82 48.5715.4 58.4717.9 3.570.51 267.2760.8 652798 0.1970.044 68.1716.0
80
c (n=3) 2.171.03 0.7070.22 2.871.59 55.2738.5 46.3723.3 4.271.94 293.8780.4 5587107 0.2170.049 76.979.4
Course number
d
1st (n=3) 2.270.38 0.7270.18 3.370.53 38.177.6 48.5712.1 3.770.64 298.4749.7 686763 0.1870.017 71.6721.0
2nd (n=3) 2.470.07 0.6670.09 3.271.07 41.5713.8 43.7711.5 4.170. 71 329.17133.2 873799 0.1470.015 62.4719.7
3rd (n=2) 2.470.00 0.7970.06 3.470.79 37.5710.2 44.6711.1 3.870.68 368.4725.9 893744 0.1470.012 72.270.4
4th (n=2) 1.971.19 0.9270.32 2.870.79 45.3711.1 69.1739.0 3.871.24 528.27180.2 12687294 0.1070.019 71.778.4
aPharmacokinetics parameters according to dose and patient population.
bFor haemodialysis patients.
cFor patients with normal renal function.
dPharmacokinetics parameters
according to course number, in which 80mgm
 2 cisplatin was administered, in haemodialysis patients. Mean7s.d.
Table 4 Pharmacokinetics parameters of etoposide
Cmax (lgml
 1) t1/2 (h) AUC (lgml
 1h) Cltot (lh
 1) Vdss (l)
Dose
a (mgm
 2)
50
b (n=1) 7.1 11.4 45.1 1.9 25.3
100
b (n=4) 12.371.63 10.873.78 91.7711.7 1.770.25 19.275.07
100
c (n=3) 16.172.66 6.370.33 93.779.3 1.570.09 10.470.73
Course number
d
1st (n=4) 12.371.63 10.873.78 91.7711.7 1.770.25 19.275.07
2nd (n=4) 11.271.83 12.973.69 95.7731.9 1.870.69 22.975.46
3rd (n=2) 10.571.41 13.574.31 106.7765.2 1.871.12 22.073.37
4th (n=2) 10.271.76 24.1718.7 125.3769.9 1.570.81 29.279.65
aPharmacokinetics parameters according to dose and patient population.
bFor haemodialysis patients.
cFor patients with normal renal function.
dPharmacokinetics parameters
according to course number, in which 100mgm
 2 etoposide was administered, in haemodialysis patients. Mean7s.d.
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study (Sauer et al, 1990).
Although all toxicity was tolerable, frequent anaemia and
thrombocytopenia prolonged in some cases were observed. As a
result of the tendency of a gradual increase in AUC and a decrease
in Cltot of t-Pt after multiple administration, toxicity would become
a more critical issue if the chemotherapy were repeated within a
short period.
In conclusion, a dose escalation study was conducted in a small
patient population together with pharmacokinetics monitoring,
and multiple administration of the full-dose combination chemo-
therapy comprising cisplatin and etoposide was shown to be
possible in haemodialysis patients. Since this study was based on
only five patients, further studies employing the same regimen for
larger patient populations are indeed warranted. In addition,
different regimens containing other recently developed agents
could certainly be investigated in a similar manner. Further studies
on optimal chemotherapy for haemodialysis patients with
malignant diseases are also called for.
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